🔥🐔 BizChicken 🐔🔥
Companies Similar to Gain Therapeutics, Inc.
Sign Up Today!
Sign up for BizChicken and discover more about the corporations around you.
Gain Therapeutics, Inc.
Site-Directed Enzyme Enhancement Therapy platform
Gain Therapeutics, Inc. is a biotechnology company developing therapies for diseases caused by protein misfolding, focusing on rare genetic diseases and neurological disorders. It utilizes its proprietary technology to discover and develop molecules targeting misfolded proteins.
Symbol: GANX
Recent Price: $2.18
Industry: Biotechnology
CEO: Mr. Gene Mack M.B.A.
Sector: Healthcare
Employees: 29
Address: 4800 Montgomery Lane, Bethesda, MD 20814
Phone: 301 500 1556
Last updated: 2024-12-31
Dyne Therapeutics, Inc.
FORCE platform
Dyne Therapeutics, Inc. is a biotechnology company focused on advancing therapeutics for genetically driven muscle diseases, including myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, using its FORCE platform.
Symbol: DYN
Recent Price: $23.65
Industry: Biotechnology
CEO: Mr. John G. Cox M.B.A.
Sector: Healthcare
Employees: 152
Address: 1560 Trapelo Road, Waltham, MA 02451
Phone: 781 786 8230
Last updated: 2024-12-31
Halozyme Therapeutics, Inc.
ENHANZE drug delivery technology
Halozyme Therapeutics, Inc. is a biopharma technology platform company specializing in enabling subcutaneous delivery of biologics using its patented ENHANZE technology. The company operates in the United States and internationally, offering products such as Hylenex recombinant and developing treatments for various medical conditions including lymphomas and immunodeficiency disorders.
Symbol: HALO
Recent Price: $47.99
Industry: Biotechnology
CEO: Dr. Helen I. Torley M.B. Ch. B., M.R.C.P.
Sector: Healthcare
Employees: 373
Address: 11388 Sorrento Valley Road, San Diego, CA 92121
Phone: 858 794 8889
Last updated: 2024-12-31
Sangamo Therapeutics, Inc.
ZFP Technology Platform
Sangamo Therapeutics, Inc. is a clinical-stage biotechnology company that develops genomic medicines using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation with a focus on transforming patients' lives.
Contact | About | About | Leadership | Leadership | About | About | About | About | About | About | About | About | About | About | Careers | Vision/Values | DEI | Benefits | About | About | About | About | About | About | About | News | Events | Vision/Values | DEI | Benefits | Careers | Careers | About | About
Symbol: SGMO
Recent Price: $2.34
Industry: Biotechnology
CEO: Dr. Alexander D. Macrae Ch.B, M.B., MRCP, Ph.D.
Sector: Healthcare
Employees: 405
Address: 501 Canal Blvd, Brisbane California, CALIFORNIA 94005
Phone: 510 970 6000
Leadership
- Sandy Macrae, M.B., Ch.B., Ph.D.,
- Gregory Davis, Ph.D., Head of Research and Technology
- Nathalie Dubois-Stringfellow, Ph.D., Chief Development Officer
- Prathyusha Duraibabu, Chief Financial Officer
- Phillip Ramsey, Head of Technical Operations
- Stephanie J. Seiler, CLP, Head of Business Development & Alliance Management
- Louise Wilkie, Global Corporate Communications and Investor Relations
- Scott Willoughby, General Counsel and Corporate Secretary
- H. Stewart Parker, Chair of the Board
- Courtney Beers, Ph.D.,
- Robert Carey,
- Kenneth Hillan, M.B. Ch.B.,
- Margaret (Peg) A. Horn, J.D.,
- John Markels, Ph.D.,
- James R. Meyers,
- Karen Smith, M.D., Ph.D., M.B.A., LLM,
Last updated: 2024-12-31
Sensei Biotherapeutics, Inc.
Immuno Phage platform
Sensei Biotherapeutics, Inc. is a biopharmaceutical company focused on the discovery and development of immunotherapies for cancer, leveraging platforms such as Immuno Phage and Tumor Microenvironment Activated Biologics.
Symbol: SNSE
Recent Price: $0.48
Industry: Biotechnology
CEO: Mr. John K. Celebi M.B.A.
Sector: Healthcare
Employees: 28
Address: 451 D Street, Rockville, MD 02210
Phone: 240 243 8000
Last updated: 2024-12-31
Sarepta Therapeutics, Inc.
EXONDYS 51, VYONDYS 53, AMONDYS 45, SRP-5051, SRP-9001, SRP-9003
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing RNA-targeted therapeutics and gene therapies for rare diseases, including treatments for Duchenne muscular dystrophy.
Contact | About | Leadership | About | About | About | Locations | About | About | About | About
Symbol: SRPT
Recent Price: $121.19
Industry: Biotechnology
CEO: Mr. Douglas S. Ingram Esq.
Sector: Healthcare
Employees: 1314
Address: 215 First Street, Cambridge, MA 02142
Phone: 617 274 4000
Leadership
- Douglas S. Ingram, President and Chief Executive Officer
- Bilal Arif, Executive Vice President, Chief Technical Operations Officer
- Diane Berry, PhD, Executive Vice President, Chief Global Policy & Advocacy Officer
- Ryan E. Brown, JD, Executive Vice President, Chief General Counsel
- Ian M. Estepan, Executive Vice President, Chief Financial Officer
- Dallan Murray, Executive Vice President, Chief Customer Officer
- Alison Nasisi, Executive Vice President, Chief People Officer
- Louise R. Rodino-Klapac, PhD, Executive Vice President, Head of R&D, Chief Scientific Officer
- Will Tilton, Senior Vice President, Head of Strategy, Chief of Staff
- M. Kathleen Behrens, PhD, Chairwoman
- Richard J. Barry,
- Kathryn Boor, PhD,
- Michael Chambers,
- Deirdre Connelly,
- Stephen L. Mayo, PhD,
- Claude Nicaise, MD,
- Hans Wigzell, MD, PhD,
- John C. Martin, PhD (In Memoriam),
- Annemieke Aartsma-Rus, PhD,
- Carsten Bönnemann, MD,
- Joy Cavagnaro, PhD, DABT, Fellow ATS,
- Kay Davies, PhD, DBE FMedSci FRS,
- Steven Gray, PhD,
- Angela J. Russell, DPhil,
Last updated: 2024-12-31
Taysha Gene Therapies, Inc.
TSHA-120, TSHA-102, TSHA-121, TSHA-118, TSHA-105, TSHA-101
Taysha Gene Therapies, Inc. focuses on developing adeno-associated virus-based gene therapies for treating monogenic diseases of the central nervous system, with a pipeline including treatments for conditions such as giant axonal neuropathy, Rett syndrome, and GM2 gangliosidosis.
Symbol: TSHA
Recent Price: $1.73
Industry: Biotechnology
CEO: Mr. Sean P. Nolan
Sector: Healthcare
Employees: 52
Address: 3000 Pegasus Park Drive, Dallas, TX 75247
Phone: 214 612 0000
Last updated: 2024-12-31
Beam Therapeutics Inc.
precision genetic medicines
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States, with a focus on conditions such as sickle cell disease, beta thalassemia, and Glycogen Storage Disease Type Ia.
About | Contact | Careers | Careers | Careers | Careers | Jobs | Careers | About | About | About | Careers | About | Jobs | Careers
Symbol: BEAM
Recent Price: $25.28
Industry: Biotechnology
CEO: Mr. John M. Evans M.B.A.
Sector: Healthcare
Employees: 472
Address: 238 Main Street, Cambridge, MA 02142
Phone: 857 327 8775
Last updated: 2024-12-31
Codexis, Inc.
Code Evolver
Codexis, Inc. discovers, develops, and sells enzymes and other proteins, offering biocatalyst products, services, and advanced protein engineering technology.
Symbol: CDXS
Recent Price: $4.67
Industry: Biotechnology
CEO: Dr. Stephen George Dilly MBBS, Ph.D.
Sector: Healthcare
Employees: 174
Address: 200 Penobscot Drive, Redwood City, CA 94063
Phone: 650 421 8100
Last updated: 2024-12-31
Cogent Biosciences, Inc.
CGT9486
Cogent Biosciences, Inc. is a biotechnology company focused on developing precision therapies for genetically defined diseases, with lead product candidate CGT9486 targeting mutations driving systemic mastocytosis and advanced gastrointestinal stromal tumors.
Symbol: COGT
Recent Price: $7.67
Industry: Biotechnology
CEO: Mr. Andrew R. Robbins M.B.A.
Sector: Healthcare
Employees: 164
Address: 200 Cambridge Park Drive, Cambridge, MA 02140
Phone: 617 945 5576
Last updated: 2024-12-31
Design Therapeutics, Inc.
Gene TAC
Design Therapeutics, Inc. is a preclinical-stage biopharmaceutical company developing therapies for genetic diseases caused by nucleotide repeat expansions. Their portfolio includes products targeting Friedreich Ataxia and Myotonic Dystrophy Type-1, as well as Gene TAC candidates for other similar diseases.
About | Contact | Careers | About | About | About | About | About | News | About | Careers | About
Symbol: DSGN
Recent Price: $6.17
Industry: Biotechnology
CEO: Mr. Pratik Shah Ph.D.
Sector: Healthcare
Employees: 57
Address: 6005 Hidden Valley Road, Carlsbad, CA 92011
Phone: 858 293 4900
Last updated: 2024-12-31
EyeGate Pharmaceuticals, Inc.
EGP-437
Eye Gate Pharmaceuticals, Inc. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutics and drug delivery systems for treating diseases of the eye.
About | Vision/Values | Directors | About | Management | Contact
Symbol: EYEG
Recent Price: $35.04
Industry: Biotechnology
CEO: Mr. Stephen From
Sector: Healthcare
Employees: 14
Address: 271 Waverley Oaks Rd Ste 108, Waltham, MASSACHUSETTS 02452
Phone: 17817889043
Leadership
- Paul Chaney, Chairman of the Board
- Morton F. Goldberg, MD, Director
- Praveen Tyle, PhD, Director
- Thomas Balland, Director
- Thomas E. Hancock, Director
- Bernard Malfroy-Camine, PhD, Director
- Mounia Chaoui, PhD, Director
Last updated: 2024-12-31
4D Molecular Therapeutics, Inc.
4D-125, 4D-110, 4D-310, 4D-150, 4D-710
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company developing product candidates using adeno-associated virus vectors, focusing on ophthalmology, cardiology, and pulmonology.
About | About | Contact | News | News | News | Careers | Careers | About | DEI | Careers | Leadership | Careers | Careers
Symbol: FDMT
Recent Price: $5.30
Industry: Biotechnology
CEO: Dr. David H. Kirn M.D.
Sector: Healthcare
Employees: 201
Address: 5858 Horton Street, EmeryVille, CA 94608
Phone: 510 505 2680
Last updated: 2024-12-31
Inozyme Pharma, Inc.
INZ-701
Inozyme Pharma, Inc. is a biopharmaceutical company focused on the development of therapeutics for rare disease conditions involving abnormal mineralization, particularly targeting ENPP1 and ABCC6 deficiencies.
Symbol: INZY
Recent Price: $2.82
Industry: Biotechnology
CEO: Dr. Douglas A. Treco Ph.D.
Sector: Healthcare
Employees: 59
Address: 321 Summer Street, Boston, MA 02210
Phone: 857 330 4340
Leadership
- Doug Treco, Ph.D., CEO, Chairman of Board of Directors
- Gayle Gironda, Senior Vice President and Chief People Officer
- Kurt Gunter, M.D., Senior Vice President and Chief Medical Officer
- Soojin Kim, Ph.D., Senior Vice President and Chief Technical Operations Officer
- Yves Sabbagh, Ph.D., Senior Vice President and Chief Scientific Officer, Chair of the Scientific Advisory Board
- Sanjay S. Subramanian, M.S., MBA, Senior Vice President and Chief Financial Officer
- Matt Winton, Ph.D., Senior Vice President and Chief Operating Officer
- Axel Bolte, MBA, Co-founder, Senior Advisor and Member of Board of Directors
- David Thompson, M.A., M.S., Ph.D., Senior Advisor, Member of Scientific Advisory Board
- Sarah Bhagat, Ph.D., Director
- Reinaldo M. Diaz, MBA, Director
- Martin Edwards M.D., MBA, Director
- Erik Harris, MBA, Director
- Rob Hopfner, Rph, Ph.D., MBA, Director
- Edward Mathers, Director
- Lynne Sullivan, MST, Director
Last updated: 2024-12-31
Omega Therapeutics, Inc.
OMEGA Epigenomic Programming platform
Omega Therapeutics, Inc. is a development-stage biopharmaceutical company leveraging its OMEGA Epigenomic Programming platform to utilize the power of epigenetics for therapeutic interventions across various diseases.
About | Vision/Values | Leadership | Leadership | About | Contact | Contact | About | About
Symbol: OMGA
Recent Price: $0.80
Industry: Biotechnology
CEO: Mr. Mahesh Karande
Sector: Healthcare
Employees: 93
Address: 20 Acorn Park Drive, Cambridge, MA 02140
Phone: 617 949 4360
Leadership
- Mahesh Karande, President & Chief Executive Officer
- Kaan Certel, Ph.D., Chief Business Officer
- Jennifer Nelson, Ph.D., Senior Vice President, Research
- Tony Mullin, Chief People Officer
- Barbara Chan, Senior Vice President, Finance and Chief Accounting Officer
- Lisamarie Fahy, Senior Vice President, Clinical Development Operations
- Joe Newman, Ph.D., Senior Vice President, Early Discovery
- Jeff Atkinson, Ph.D., Vice President, Technical Operations
- Eva Stroynowski, Senior Vice President, Investor Relations and Corporate Affairs
Last updated: 2024-12-31
Rocket Pharmaceuticals, Inc.
Gene Therapies
Rocket Pharmaceuticals, Inc. is a biotechnology company focused on developing gene therapies for rare and devastating diseases, with multiple clinical-stage programs targeting disorders such as fanconi anemia, leukocyte adhesion deficiency-I, pyruvate kinase deficiency, and Danon disease.
Symbol: RCKT
Recent Price: $12.03
Industry: Biotechnology
CEO: Dr. Gaurav D. Shah M.D.
Sector: Healthcare
Employees: 268
Address: 9 Cedarbrook Drive, Cranbury, NJ 08512
Phone: 609 659 8001
Last updated: 2024-12-31
TScan Therapeutics, Inc.
T cell receptor-engineered T cell therapies
TScan Therapeutics, Inc. is a preclinical-stage biopharmaceutical company that develops T cell receptor-engineered T cell therapies for cancer treatment. It is working on therapies for hematologic malignancies and solid tumors, as well as vaccines for infectious diseases like SARS-CoV-2.
About | About | Management | Directors | About | About | Contact | Careers | Careers | Careers | About | About
Symbol: TCRX
Recent Price: $3.00
Industry: Biotechnology
CEO: Dr. Gavin MacBeath Ph.D.
Sector: Healthcare
Employees: 175
Address: 830 Winter Street, Waltham, MA 02451
Phone: 857 399 9500
Leadership
- Stephen Biggar, M.D., Ph.D., Partner at Baker Bros. Advisors LP
- Katina Dorton, J.D., M.B.A., CFO of Nodthera
- Gabriela Gruia, M.D., Chief Development Officer at Ichnos Sciences
- Barbara Klencke, M.D., Former Chief Medical Officer and Chief Development Officer of Sierra Oncology Inc.
- Gavin MacBeath, Ph.D., CEO of TSCAN
- Garry Nicholson, Former President of Pfizer Oncology
- R. Keith Woods, Former Chief Operating Officer of argenx
Last updated: 2024-12-31
Entrada Therapeutics, Inc.
ENTR-601-44
Entrada Therapeutics, Inc. develops endosomal escape vehicle (EEV) therapeutics for treating neuromuscular diseases, with a lead product candidate ENTR-601-44 in preclinical trials for Duchenne muscular dystrophy and myotonic dystrophy type 1.
About | Contact | Contact | Careers | Careers | Careers | About | About | Careers | Careers | Careers | Careers | Careers | Careers | About
Symbol: TRDA
Recent Price: $17.37
Industry: Biotechnology
CEO: Mr. Dipal Doshi
Sector: Healthcare
Employees: 168
Address: 6 Tide Street, Boston, MA 02210
Phone: 857 520 9158
Last updated: 2024-12-31
MeiraGTx Holdings plc
Gene Therapy Treatments
Meira GTx Holdings plc is a clinical stage gene therapy company developing treatments for serious diseases, including ocular diseases, xerostomia, and neurodegenerative conditions. They are in various stages of clinical development for several gene therapy programs and have a research collaboration with Janssen Pharmaceuticals.
About | Leadership | About | Contact | About | About | About | News | About | About | About | Directors
Symbol: MGTX
Recent Price: $5.89
Industry: Biotechnology
CEO: Dr. Alexandria Forbes Ph.D.
Sector: Healthcare
Employees: 387
Address: 430 East 29th Street, New York, NY 10016
Phone: 646 860 7985
Leadership
- Alexandria Forbes, Ph.D., Board Member, President and Chief Executive Officer
- Richard Giroux, Chief Operating Officer and Chief Financial Officer
- Stuart Naylor, Ph.D., Chief Development Officer
- Robert K. Zeldin, M.D., Chief Medical Officer
- Robert Wollin, JD, General Counsel and Secretary
- Alastair Leighton, Ph.D, SVP, Manufacturing and Supply Chain
- Christine Sheehy, SVP, Global Integration
- Tim Randall, SVP, Risk and Internal Controls
- Michel Michaelides, M.D., Head of Clinical Ophthalmology
- Tassos Georgiadis, Ph.D., Vice President, Preclinical Development
- Keith R. Harris, Ph.D., Chairman of the Board
- Ellen Hukkelhoven, Ph.D., Board Member
- Lord Mendoza, Independent Board Member
- Nicole Seligman, Independent Board Member
- Thomas E. Shenk, Ph.D., Independent Board Member
- Debra Yu, M.D., Independent Board Member
Last updated: 2024-12-31
Tango Therapeutics, Inc.
TNG908
Tango Therapeutics, Inc. is a biotechnology company focused on discovering and developing drugs for cancer treatment, with a lead program TNG908 targeting cancers with methylthioadenosine phosphorylase deletions. The company also works on therapies for BRCA1/2-mutant and STK11-mutant cancers and collaborates with Gilead Sciences, Inc.
Symbol: TNGX
Recent Price: $3.10
Industry: Biotechnology
CEO: Dr. Barbara L. Weber M.D.
Sector: Healthcare
Employees: 140
Address: 100 Binney Street, Cambridge, MA 02142
Phone: 857 320 4900
Last updated: 2024-12-31